Taken together, these findings suggest that tirzepatide may reduce hepatic lipid uptake by down-regulating the expression of CD36 and OBP2A in the liver, thereby alleviating intrahepatic lipid accumulation in MASLD. The gene discussed is CD36; the disease is metabolic dysfunction-associated steatotic liver disease.